Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Platinum-Doublet in Advanced EGFR-wt Non-squamous NSCLC
NCT03201146Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03201146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201146.